ACCi in combination with both doses of fenofibrate treatment, versus ACCi alone in the mixed noncirrhotic and cirrhotic NASH patients, significantly lowered mean LDL-apoB FRR (± SEM) (33 ± 4 from 46 ± 6%/day, P = 0.032, Fig. 3A) and LDL-apoB ASR (± SEM) (34 ± 4 from 45 ± 4 mg/dl/day, P = 0.026, Fig. 3B). This evidence concerns the gene APOB and metabolic dysfunction-associated steatohepatitis.